The text provides unaudited financial information for Boston Scientific Corporation for the three and nine months ended September 30, 2022, containing consolidated statements of operations, comprehensive income (loss), balance sheets, stockholders' equity, and cash flows. It highlights key financial metrics such as net sales, operating expenses, income before taxes, net income, stockholders' equity details, and cash flow activities, giving insights into the company's financial performance during the specified periods. Another aspect covered in the text is the company's adherence to financial instruments and fair value measurements as per FASB ASC Topic 815 and FASB ASC Topic 820. This includes discussing the reclassification of gains or losses from Accumulated Other Comprehensive Income (AOCI) to earnings, changes in fair value for designated debt instruments, and the classification of derivative and nonderivative assets and liabilities. The company utilizes Level 1, Level 2, and Level 3 inputs for fair value measurement, the fair value hierarchy for financial assets and liabilities, and Level 3 inputs related to licensing arrangements. Additionally, details on fair value measurements of outstanding debts like senior notes and credit facilities are provided.
Boston Scientific Corporation is a global medical device company that has been impacted by the COVID-19 pandemic, facing challenges such as raw material shortages, labor market issues, and economic uncertainty. Despite these obstacles, the company continues to focus on its long-term goals and commitment to sustainable practices. In terms of financial performance, their net sales have increased, with reported net income for the third quarter of 2022 being $174 million and $516 million for the first nine months. The company provides a breakdown of their financial results, including adjusted net income and non-GAAP adjustments. The text delves into various financial items such as contingent consideration net expenses, restructuring charges, litigation-related net charges, gains on disposal of businesses and assets, interest expenses, and tax rates, among others. Details on liquidity, capital resources, contractual obligations, equity, legal matters, recent accounting pronouncements, and cybersecurity measures are also discussed. The company's financial statements, critical accounting estimates, and information on acquisitions, divestitures, and investments are highlighted, along with their financial performance, debt obligations, and compliance with financial covenants. Overall, despite the challenges posed by the pandemic and economic conditions, Boston Scientific Corporation remains focused on its mission and strategic growth.
The company operates a risk management program to mitigate market risks from currency exchange rates and interest rates related to their global medical device business. They use derivative financial instruments for this purpose, with gains and losses on these instruments offsetting each other. Currency risk includes firm commitments, intercompany transactions, and investments in subsidiaries, managed using both derivative and non-derivative instruments. Interest rate risk is mainly from U.S. dollar borrowings, managed historically through interest rate derivative instruments. The company had no interest rate derivatives outstanding as of recent dates, with most debt obligations being at fixed interest rates. Detailed information on derivative financial instruments can be found in the company's financial statements.
Management, along with the CEO and CFO, evaluated the effectiveness of disclosure controls and procedures as of September 30, 2022, finding them to be effective. There were no significant changes in internal control over financial reporting in the third quarter of 2022. However, a new global enterprise resource planning (ERP) system implementation is underway in phases over the next few years, leading to process, procedure, and internal control changes that will be evaluated quarterly to ensure their impact on financial reporting.
The text refers to legal proceedings and directs the reader to look at Note G - Income Taxes and Note H - Commitments and Contingencies in the unaudited financial statements in the Quarterly Report on Form 10-Q for more information.
Consider the risk factors discussed in Part 1A of the most recent Annual Report filed on Form 10-K, which could significantly impact the company's business, financial position, or future performance.
I am ready to assist. Please go ahead and provide me with the text that you would like me to summarize.
I am ready to assist with providing a summary. Please go ahead and share the text with me.
I'm sorry, but I cannot summarize the text without the actual content. Please provide the text that you would like me to summarize.
The text covers various legal matters faced by a company, such as settlement agreements and product liability cases, as well as financial information like dividends paid and stock repurchases. It also outlines the revenue generated by different business segments and regions. Additionally, it delves into the financial performance of a medical technology company, focusing on segments such as Endoscopy and Cardiology, detailing net sales growth and operational performance. There is also a discussion regarding gross profit margin changes, operating expenses, and factors affecting the company's profitability, including inflation, foreign currency fluctuations, and macro-economic challenges.
The text discusses various exhibits, including indentures and senior notes, related to Boston Scientific Corporation. It also includes certifications of the Chief Executive Officer and Chief Financial Officer as well as Inline XBRL documents. The report was signed on behalf of Boston Scientific Corporation on November 3, 2022, by Daniel J. Brennan, the Executive Vice President and Chief Financial Officer.
